Sentara Health Plans

Medicaid

Galectin 3 (LGALS3), Medical 304

Table of Content

Effective Date	12/2012
Next Review Date	6/2025
Coverage Policy	Medical 304
Version	4

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Purpose:

This policy addresses Galectin 3 (LGALS3).

Description & Definitions:

A lab analysis for Galectin 3 (LGALS3) a protein that is involved with cell growth, cell death, cell division cycle, cell adhesions and other cell functions. Mutations are associated with heart disease, stroke, cancer, fibrosis and inflammation.

Criteria:

Galectin 3 (LGALS3) is considered **not medically necessary** for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
82777	Galectin-3

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2024: June – criteria updated references updated
- 2020: January
- 2016: January, April
- 2015: January, February, October
- 2014: July, December
- 2013: January, February, March, July, August, September

Reviewed Dates:

- 2023: June
- 2022: June
- 2021: August
- 2020: August
- 2019: May
- 2018: May
- 2016: June, July

Effective Date:

- December 2012

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

Federal Register. Daily Journal of the United States Government. Retrieved 5.30.2024. https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=galectin+3

U.S. Food and Drug Administration. Galectin-3 Reagent Kit . No date. Retrieved 5.30.2024. https://www.accessdata.fda.gov/cdrh_docs/reviews/K140436.pdf

Hayes. A symplr company. Health Technology Assessment. Review :Aug 20, 2015. Galectin-3 In Vitro Diagnostic Assay (BG Medicine Inc.) For The Management Of Patients With Chronic Heart Failure. Retrieved 5.30.2024. https://evidence.hayesinc.com/report/htb.galectin2719

MCG Informed Care Strategies. Retrieved 5.30.2024. https://careweb.careguidelines.com/ed27/index.html

Centers for Medicare and Medicaid Services. CMS.gov. Retrieved 5.30.2024. https://www.cms.gov/search/cms?keys=82777

Commonwealth of Virginia. Department of Medical Assistance Services. Retrieved 5.30.2024. https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=82777&gsc.sort=

Commonwealth of Virginia. Department of Medical Assistance Services. DMAS Fee Schedule. Retrieved 5.30.2024 https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT

National Comprehensive Cancer Network. Retrieved 5.30.2024. https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=galectin

Carelon clinical guidelines and pathways. Retrieved 5.30.2024. https://guidelines.carelonmedicalbenefitsmanagement.com/no-search-results-found/

Avalon. Biomarkers for Myocardial Infarction and Chronic Heart Failure. Policy Number: AHS – G2150. 1.2.2024. Retrieved 5.30.2024. https://www.avalonhcs.com/wp-content/uploads/sentarahealth/G2150%20Biomarkers%20for%20Myocardial%20Infarction%20and%20Chronic%20Heart%20Failure.pdf

BlueCross of Oklahoma. ST2 Assay for Chronic Heart Failure Policy Number: CPCPLAB040 Version 1.0 Plan Effective Date: Nov. 1, 2022. Retrieved 5.30.2024. https://www.bcbsok.com/docs/provider/ok/standards/cpcp/avalon/cpcplab040-st2-assay-for-chronic-heart-failure-09-01-22.pdf

Hara, A., Niwa, M., Noguchi, K., Kanayama, T., Niwa, A., Matsuo, M., Hatano, Y., & Tomita, H. (2020). Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules, 10(3), 389. Retrieved 5.30.2024. https://doi.org/10.3390/biom10030389

Sygitowicz, G., Maciejak-Jastrzębska, A., & Sitkiewicz, D. (2021). The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. Biomolecules, 12(1), 46. Retrieved 5.30.2024. https://doi.org/10.3390/biom12010046

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to by medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Keywords:

SHP Galectin 3, LGALS3, SHP Medical 304, IgE-Binding Protein, MAC-2, Lectin L-29, L-34 CBP-30, Gal-3, Advanced Glycation End-Product Receptor 3, Lectin, Galactoside-Binding, Soluble, 3, Carbohydrate-Binding Protein 35, CBP 35, Galactose-Specific Lectin 3, Laminin-Binding Protein, 35 KDa Lectin, Galactoside-Binding Protein, GALBP, heart disease, stroke, cancer, fibrosis, inflammation, cell growth, cell death, cell division cycle, cell adhesions, L31; GAL3; MAC2; GALIG; LGALS2